These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38555274)

  • 1. Molnupiravir for the treatment of COVID-19 outpatients: An updated meta-analysis.
    Cheema HA; Abdul Rab S; Butt M; Jafar U; Shahid A; Rehman AU; Lee KY; Sahra S; Sah R
    J Microbiol Immunol Infect; 2024 Jun; 57(3):396-402. PubMed ID: 38555274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molnupiravir in COVID-19: A systematic review of literature.
    Singh AK; Singh A; Singh R; Misra A
    Diabetes Metab Syndr; 2021; 15(6):102329. PubMed ID: 34742052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of effectiveness and safety of molnupiravir versus sotrovimab for COVID-19: A systematic review and meta-analysis.
    Amani B; Amani B
    Immun Inflamm Dis; 2024 Apr; 12(4):e1262. PubMed ID: 38652021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.
    Jayk Bernal A; Gomes da Silva MM; Musungaie DB; Kovalchuk E; Gonzalez A; Delos Reyes V; Martín-Quirós A; Caraco Y; Williams-Diaz A; Brown ML; Du J; Pedley A; Assaid C; Strizki J; Grobler JA; Shamsuddin HH; Tipping R; Wan H; Paschke A; Butterton JR; Johnson MG; De Anda C;
    N Engl J Med; 2022 Feb; 386(6):509-520. PubMed ID: 34914868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19.
    Singh AK; Singh A; Singh R; Misra A
    Diabetes Metab Syndr; 2022 Feb; 16(2):102396. PubMed ID: 35051686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molnupiravir versus favipiravir in at-risk outpatients with COVID-19: A randomized controlled trial in Thailand.
    Salvadori N; Jourdain G; Krittayaphong R; Siripongboonsitti T; Kongsaengdao S; Atipornwanich K; Sakulkonkij P; Angkasekwinai N; Sirijatuphat R; Chusri S; Mekavuthikul T; Apisarnthanarak A; Srichatrapimuk S; Sungkanuparph S; Kirdlarp S; Phongnarudech T; Sangsawang S; Napinkul P; Achalapong J; Khusuwan S; Pratipanawat P; Nookeu P; Danpipat N; Leethong P; Hanvoravongchai P; Sukrakanchana PO; Auewarakul P
    Int J Infect Dis; 2024 Jun; 143():107021. PubMed ID: 38561040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molnupiravir: A new candidate for COVID-19 treatment.
    Pourkarim F; Pourtaghi-Anvarian S; Rezaee H
    Pharmacol Res Perspect; 2022 Feb; 10(1):e00909. PubMed ID: 34968008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ivermectin for preventing and treating COVID-19.
    Popp M; Stegemann M; Metzendorf MI; Gould S; Kranke P; Meybohm P; Skoetz N; Weibel S
    Cochrane Database Syst Rev; 2021 Jul; 7(7):CD015017. PubMed ID: 34318930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19.
    Imran M; Kumar Arora M; Asdaq SMB; Khan SA; Alaqel SI; Alshammari MK; Alshehri MM; Alshrari AS; Mateq Ali A; Al-Shammeri AM; Alhazmi BD; Harshan AA; Alam MT; Abida
    Molecules; 2021 Sep; 26(19):. PubMed ID: 34641339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Remdesivir for the treatment of COVID-19.
    Ansems K; Grundeis F; Dahms K; Mikolajewska A; Thieme V; Piechotta V; Metzendorf MI; Stegemann M; Benstoem C; Fichtner F
    Cochrane Database Syst Rev; 2021 Aug; 8(8):CD014962. PubMed ID: 34350582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virology and safety profile of Molnupiravir at three different doses for treatment of SARS-CoV-2: a systematic review and meta-analysis.
    Sukaina M; Shuja SH; Rehan ST; Ochani S; Sheryar M
    APMIS; 2024 Mar; 132(3):139-151. PubMed ID: 38288881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Molnupiravir Treatment for COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Tian F; Feng Q; Chen Z
    Int J Antimicrob Agents; 2023 Aug; 62(2):106870. PubMed ID: 37245600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis.
    Wen W; Chen C; Tang J; Wang C; Zhou M; Cheng Y; Zhou X; Wu Q; Zhang X; Feng Z; Wang M; Mao Q
    Ann Med; 2022 Dec; 54(1):516-523. PubMed ID: 35118917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of RNA-Dependent RNA Polymerase Inhibitors, Molnupiravir and VV116, for Oral Treatment of COVID-19: A Meta-Analysis.
    Zheng Z; Zhou J; Song Y
    Iran J Med Sci; 2024 May; 49(5):275-285. PubMed ID: 38751873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19.
    Painter GR; Natchus MG; Cohen O; Holman W; Painter WP
    Curr Opin Virol; 2021 Oct; 50():17-22. PubMed ID: 34271264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of molnupiravir for the treatment of SARS-CoV-2 infection: a systematic review and meta-analysis.
    Malin JJ; Weibel S; Gruell H; Kreuzberger N; Stegemann M; Skoetz N
    J Antimicrob Chemother; 2023 Jul; 78(7):1586-1598. PubMed ID: 37170886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Remdesivir for the treatment of COVID-19.
    Grundeis F; Ansems K; Dahms K; Thieme V; Metzendorf MI; Skoetz N; Benstoem C; Mikolajewska A; Griesel M; Fichtner F; Stegemann M
    Cochrane Database Syst Rev; 2023 Jan; 1(1):CD014962. PubMed ID: 36695483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy and safety of molnupiravir for nonhospitalized and hospitalized patients with COVID-19: A systematic review and meta-analysis of randomized control trials.
    Huang PY; Liu TH; Wu JY; Tsai YW; Lai CC
    J Med Virol; 2023 Mar; 95(3):e28621. PubMed ID: 36846901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.
    Singh B; Ryan H; Kredo T; Chaplin M; Fletcher T
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD013587. PubMed ID: 33624299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: Systematic review and network meta-analysis.
    Zur M; Peselev T; Yanko S; Rotshild V; Matok I
    Antiviral Res; 2024 Jan; 221():105768. PubMed ID: 38056602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.